<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/5E9E5F30-A127-4243-AB12-B19B7A50D0E7"><gtr:id>5E9E5F30-A127-4243-AB12-B19B7A50D0E7</gtr:id><gtr:name>Unlisted</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/DD21B8FC-26A6-4A3A-9A23-207B6667CB41"><gtr:id>DD21B8FC-26A6-4A3A-9A23-207B6667CB41</gtr:id><gtr:name>University of Pittsburgh</gtr:name><gtr:address><gtr:line1>University of Pittsburgh</gtr:line1><gtr:line4>Pittsburgh</gtr:line4><gtr:line5>Pennsylvania</gtr:line5><gtr:postCode>PA 15260</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/82200E1A-04DA-42F5-80F3-B0FF026643BD"><gtr:id>82200E1A-04DA-42F5-80F3-B0FF026643BD</gtr:id><gtr:name>University of Copenhagen</gtr:name><gtr:address><gtr:line1>Norregade 10</gtr:line1><gtr:line2>Postboks 2177</gtr:line2><gtr:line4>Copenhagen K</gtr:line4><gtr:line5>DK-1017</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Denmark</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/D657B59F-F040-46B5-A35B-D457C06CE596"><gtr:id>D657B59F-F040-46B5-A35B-D457C06CE596</gtr:id><gtr:name>Becton, Dickinson and Company (BD)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/1D747F83-0211-40DF-84E7-DB44C10B03F1"><gtr:id>1D747F83-0211-40DF-84E7-DB44C10B03F1</gtr:id><gtr:name>Fred Hutchinson Cancer Research Center (FHCRC)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/E71BE209-CC55-4935-A1B7-188175235B1F"><gtr:id>E71BE209-CC55-4935-A1B7-188175235B1F</gtr:id><gtr:name>Institute of Translational Medicine</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/8218E276-85FA-4CD5-86AA-232A830B5037"><gtr:id>8218E276-85FA-4CD5-86AA-232A830B5037</gtr:id><gtr:name>University of Texas at San Antonio</gtr:name><gtr:address><gtr:line1>One UTSA Circle</gtr:line1><gtr:line4>San Antonio</gtr:line4><gtr:line5>TX 78249-1644</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/835A53CE-63D8-47EA-9216-60589F307EAE"><gtr:id>835A53CE-63D8-47EA-9216-60589F307EAE</gtr:id><gtr:name>School of Medicine Liverpool</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/68D0E3C9-9246-4CFC-B5E9-48584CF82993"><gtr:id>68D0E3C9-9246-4CFC-B5E9-48584CF82993</gtr:id><gtr:name>University of Manchester</gtr:name><gtr:address><gtr:line1>Oxford Road</gtr:line1><gtr:city>Manchester</gtr:city><gtr:postCode>M13 9PL</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:department>Maternal &amp; Fetal Medicine</gtr:department><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/5E9E5F30-A127-4243-AB12-B19B7A50D0E7"><gtr:id>5E9E5F30-A127-4243-AB12-B19B7A50D0E7</gtr:id><gtr:name>Unlisted</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/DD21B8FC-26A6-4A3A-9A23-207B6667CB41"><gtr:id>DD21B8FC-26A6-4A3A-9A23-207B6667CB41</gtr:id><gtr:name>University of Pittsburgh</gtr:name><gtr:address><gtr:line1>University of Pittsburgh</gtr:line1><gtr:line4>Pittsburgh</gtr:line4><gtr:line5>Pennsylvania</gtr:line5><gtr:postCode>PA 15260</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/82200E1A-04DA-42F5-80F3-B0FF026643BD"><gtr:id>82200E1A-04DA-42F5-80F3-B0FF026643BD</gtr:id><gtr:name>University of Copenhagen</gtr:name><gtr:address><gtr:line1>Norregade 10</gtr:line1><gtr:line2>Postboks 2177</gtr:line2><gtr:line4>Copenhagen K</gtr:line4><gtr:line5>DK-1017</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Denmark</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/D657B59F-F040-46B5-A35B-D457C06CE596"><gtr:id>D657B59F-F040-46B5-A35B-D457C06CE596</gtr:id><gtr:name>Becton, Dickinson and Company (BD)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/1D747F83-0211-40DF-84E7-DB44C10B03F1"><gtr:id>1D747F83-0211-40DF-84E7-DB44C10B03F1</gtr:id><gtr:name>Fred Hutchinson Cancer Research Center (FHCRC)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/E71BE209-CC55-4935-A1B7-188175235B1F"><gtr:id>E71BE209-CC55-4935-A1B7-188175235B1F</gtr:id><gtr:name>Institute of Translational Medicine</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/8218E276-85FA-4CD5-86AA-232A830B5037"><gtr:id>8218E276-85FA-4CD5-86AA-232A830B5037</gtr:id><gtr:name>University of Texas at San Antonio</gtr:name><gtr:address><gtr:line1>One UTSA Circle</gtr:line1><gtr:line4>San Antonio</gtr:line4><gtr:line5>TX 78249-1644</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/835A53CE-63D8-47EA-9216-60589F307EAE"><gtr:id>835A53CE-63D8-47EA-9216-60589F307EAE</gtr:id><gtr:name>School of Medicine Liverpool</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/68D0E3C9-9246-4CFC-B5E9-48584CF82993"><gtr:id>68D0E3C9-9246-4CFC-B5E9-48584CF82993</gtr:id><gtr:name>University of Manchester</gtr:name><gtr:address><gtr:line1>Oxford Road</gtr:line1><gtr:city>Manchester</gtr:city><gtr:postCode>M13 9PL</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/BC926EAB-A44D-4439-B901-7437B838066F"><gtr:id>BC926EAB-A44D-4439-B901-7437B838066F</gtr:id><gtr:firstName>Lesley</gtr:firstName><gtr:surname>Fallowfield</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/1FFD79A0-0681-4141-A504-FDE130EF7F33"><gtr:id>1FFD79A0-0681-4141-A504-FDE130EF7F33</gtr:id><gtr:firstName>Mahesh</gtr:firstName><gtr:surname>Parmar</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/1C19F7AF-5A4B-4B2D-A649-3A45425290A4"><gtr:id>1C19F7AF-5A4B-4B2D-A649-3A45425290A4</gtr:id><gtr:firstName>Ian</gtr:firstName><gtr:surname>Jacobs</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/8E6DFD2D-32DA-416D-96AB-E61FC1BFC7A4"><gtr:id>8E6DFD2D-32DA-416D-96AB-E61FC1BFC7A4</gtr:id><gtr:firstName>Alistair</gtr:firstName><gtr:otherNames>James</gtr:otherNames><gtr:surname>Mcguire</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/8A528B55-524E-4519-A006-AF99A98A3D40"><gtr:id>8A528B55-524E-4519-A006-AF99A98A3D40</gtr:id><gtr:firstName>Steven</gtr:firstName><gtr:surname>Skates</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/B402EBFA-B38F-4EE6-BAFA-8DD188E0B810"><gtr:id>B402EBFA-B38F-4EE6-BAFA-8DD188E0B810</gtr:id><gtr:firstName>Stuart</gtr:firstName><gtr:surname>Campbell</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=G9901012"><gtr:id>2F385279-5A8C-4122-951B-294BDC21405E</gtr:id><gtr:title>United Kingdom Collaborative Trial of Ovarian Cancer (UKCTOCS)</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G9901012</gtr:grantReference><gtr:abstractText>Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.</gtr:abstractText><gtr:technicalSummary>Ovarian cancer (OC) is responsible for over 4000 deaths in the UK each year. The overall 5 year survival rate is only 35% but women diagnosed with early stage disease have survival rates as high as 90%. During the last decade the applicants have conducted large prospective screening trials which have identified two screening strategies with encouraging sensitivity and specificity for preclinical detection of OC. The proposal is for a three armed randomised controlled trial to assess the impact of these screening strategies in the general population. A total of 200,000 postmenopausal women, aged 50-74 years will be randomised in a 1:1:2 ratio to ultrasound screening, multimodal screening or a control group who will not be screened. Screening will occur in 12 collaborating gynaecological oncology centres in the UK and participants randomised to screening will undergo 6 screens at annual intervals. Ultrasound screening will involve a level I screen with transvaginal ultrasonography (TVS) to document abnormalities of ovarian morphology and volume. Multimodal screening will involve a level I screen with CA 125 to calculate the Risk of OC. Women with abnormal level I screening results in either group will be recalled for a level II screen with TVS and the small proportion of women with abnormal level II results will be referred for specialist surgical assessment. All participants will be followed up by postal questionnaire and via the cancer registry. The primary end point of the study will be OC mortality at 7 years after randomisation. Additional end points will include quality of life, health economics, morbidity and compliance with screening. The trial has 90% power to detect a 30% reduction in OC mortality in the screened groups compared to the control group. The results of the trial will form the basis for an informed decision about the place of general population screening for OC.</gtr:technicalSummary><gtr:fund><gtr:end>2012-11-03</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2000-11-04</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>17436516</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs><gtr:artisticAndCreativeProductOutput><gtr:description>A painting of a primary ovarian follicle was created by a commissioned artist (Dr Lizzie Burns). The image of painting was digitized so that each dot represented 8 women participants in the trial. This digitized image was then used on the front of a card that was posted at the end of the screening period to all the the UKCTOCS volunteers to thank them for their participation in the trial. mailin was performed in collaboration with the charity, The Eve Appeal. The package also contained information about the trial and what was to happen during the follow-up period of UKCTOCS.</gtr:description><gtr:id>A04EDB7E-509D-4A8D-BF3C-0ECA93AD32C3</gtr:id><gtr:impact>Approximately 30,000 replies were received back from the women within three weeks of mailing- expressing huge appreciation of the trial and what its was trying to achieve, that the team had 'remembered' the volunteers. Many volunteers touched by the gesture. In women where a cancer had been detected, felt that the trial had saved their lives. Added benefit was that the The Eve Appeal database of donors was increased .</gtr:impact><gtr:title>Creation of artwork for thank you card for UKCTOCS volunteers</gtr:title><gtr:type>Artwork</gtr:type><gtr:url>https://www.ucl.ac.uk/instituteforwomenshealth/news/oldnewsletters/new-letters-tabbed-box/2012/2012march-april.pdf</gtr:url><gtr:yearFirstProvided>2012</gtr:yearFirstProvided></gtr:artisticAndCreativeProductOutput></gtr:artisticAndCreativeProductOutputs><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Reading</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>School of Biological Sciences Reading</gtr:department><gtr:description>Proteomic profiling of human sera for biomarker discovery</gtr:description><gtr:id>E1A33DBB-A2BD-4647-970F-7DB60C01E9F6</gtr:id><gtr:impact>Five peer-reviewed publications. Award of CR-UK Programme Grant in risk prediction and ealry detection of ovarian cancer. The collaboration on biomarker discovery continues.</gtr:impact><gtr:partnerContribution>The development and application of different proteomic technologies for serum biomarker discovery and data analysis</gtr:partnerContribution><gtr:piContribution>The development of technologies for serum profiling and the provision of clinical, control and pre-diagnosis serum samples from cases of ovarian, breast cancer and heart disease</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Copenhagen</gtr:collaboratingOrganisation><gtr:country>Denmark, Kingdom of</gtr:country><gtr:description>cancer specific serum response and development of colorectal cancer</gtr:description><gtr:id>1F433C9D-A00B-449D-9B1E-319425E41DB3</gtr:id><gtr:impact>Two publications: 
Pedersen et al BJC 2013;15;108(1):107-14.
Pedersen et al International journal of cancer Journal international du cancer. 2013 Oct 11.</gtr:impact><gtr:partnerContribution>bioassays and expertise in colorectal cancer</gtr:partnerContribution><gtr:piContribution>study design, serum samples and data interpretion</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London (UCL)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>University College London (UCL), UCL Cancer Institute</gtr:department><gtr:description>Hormonal Profile in Breast cancer</gtr:description><gtr:id>858B64D0-D305-492A-A8EA-F0E4E70AEEDA</gtr:id><gtr:impact>A PhD awarded and two publications:
Fourkala EO et al Endocrine-related cancer. 2012 Apr;19(2):137-47.
Fourkala EO et al Br J Cancer. 2012 Jun 5;106(12):1910-6.</gtr:impact><gtr:partnerContribution>Expertise in Breast cancer</gtr:partnerContribution><gtr:piContribution>Samples and data from UKCTOCS volunteers who developed breast cancer</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Pittsburgh</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>School of Medicine Pittsburgh</gtr:department><gtr:description>Multianalyte assay for early diagnosis of ovarian cancer</gtr:description><gtr:id>ED4BCE44-F1E1-4994-BA28-8C88B0204DD7</gtr:id><gtr:impact>Project ongoing - intial sample sets have been shipped to our Collaborators and are being assayed. Results from sample testing are pending.</gtr:impact><gtr:partnerContribution>Enabling assessment of serum biomarkers in multiplex system.</gtr:partnerContribution><gtr:piContribution>Input into the study design and data interpretation. Preclinical samples and data from ovarian cancer cases and controls</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London (UCL)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>UCL Institute of Hepatology</gtr:department><gtr:description>Discovery of biomarkers of pancreatobiliary disease</gtr:description><gtr:id>06264598-B62E-4A43-B0D7-E9046DEB995B</gtr:id><gtr:impact>Award of PancSoc GB&amp;amp;I pump priming grant to validate reported markers of pancreatic cancer in prediagnosis and control samples. Award of CRUK TRICC pilot grant, CRUK BIDD Project grant and Pancreatic cancer UK grant aimed at discovery of serum biomarkers of pancreatic cancer. Identification of promising candidate biomarkers with one publication accepted and another submitted.</gtr:impact><gtr:partnerContribution>Provision of expertise in pancreatic and biliary tract cancers and access to clinical samples for biomarker discoveryProvision of expertise in pancreatic cancer and access to additional case control serum samples relevant to biomarker discovery</gtr:partnerContribution><gtr:piContribution>Samples from UKCTOCS have been provided to collaborators for biomarker testing and discovery using complementary techniques to those applied at UCL</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Institute of Translational Medicine</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Molecular and Clinical Cancer Medicine</gtr:department><gtr:description>Discovery of biomarkers of pancreatobiliary disease</gtr:description><gtr:id>F31ACC13-B205-4EDD-8B00-3BA7579B8FAF</gtr:id><gtr:impact>Award of PancSoc GB&amp;amp;I pump priming grant to validate reported markers of pancreatic cancer in prediagnosis and control samples. Award of CRUK TRICC pilot grant, CRUK BIDD Project grant and Pancreatic cancer UK grant aimed at discovery of serum biomarkers of pancreatic cancer. Identification of promising candidate biomarkers with one publication accepted and another submitted.</gtr:impact><gtr:partnerContribution>Provision of expertise in pancreatic and biliary tract cancers and access to clinical samples for biomarker discoveryProvision of expertise in pancreatic cancer and access to additional case control serum samples relevant to biomarker discovery</gtr:partnerContribution><gtr:piContribution>Samples from UKCTOCS have been provided to collaborators for biomarker testing and discovery using complementary techniques to those applied at UCL</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London (UCL)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>UCL Institute of Cardiovascular Science</gtr:department><gtr:description>Risk factors for coronary artery disease</gtr:description><gtr:id>E27487D1-E8C5-4081-9388-9EA523F92D66</gtr:id><gtr:impact>ULCH CBRC grant. Multidisciplinary - Epidemiology and Public Health, Cardiovascular Genetics and Gynaecological Oncology.
Data from the study will go into the UCLEB consortia.</gtr:impact><gtr:partnerContribution>Expertise in Heart disease</gtr:partnerContribution><gtr:piContribution>Study design , grant application and identification of appropriate sample sets.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Becton, Dickinson and Company (BD)</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Pilot study-Ovarian Cancer Biomarker discovery</gtr:description><gtr:id>6F80EB40-A015-4503-8F74-BF55CAE10763</gtr:id><gtr:impact>No outputs so far as BD withdrew from collaboration.
 The tem was multi-disciplinary involving biomedical scientists, physicians and statistics</gtr:impact><gtr:partnerContribution>Ovarian cancer multimarker assays</gtr:partnerContribution><gtr:piContribution>Provision of serum and data</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Fred Hutchinson Cancer Research Center (FHCRC)</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Molecular Diagnostics Program (FHCRC)</gtr:department><gtr:description>Biomarker assessment in preclinical samples from UKCTOCS</gtr:description><gtr:id>A525BE7E-91D6-44A1-B673-7AAB79ED23E0</gtr:id><gtr:impact>Bilateral partnership - Agreement, Ethics and MTA in place.</gtr:impact><gtr:partnerContribution>Access to novel biomarker assays</gtr:partnerContribution><gtr:piContribution>Providing samples and data from controls and ovarian cancer cases</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London (UCL)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>University College London (UCL), UCL Cancer Institute</gtr:department><gtr:description>MRC Proteomics biomarker discovery</gtr:description><gtr:id>CB9EA32A-A992-4DB8-8795-7272475C3DE4</gtr:id><gtr:impact>MRC Grant for proteomic discovery of biomarkers for ovarian cancer.Project complete. Details of publications are provided in the publications section.</gtr:impact><gtr:piContribution>Use of UKCTOCS samples for the biomarker discovery project.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London (UCL)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>UCL Institute of Hepatology</gtr:department><gtr:description>Discovery of biomarkers of biliary tract and pancreatic cancer</gtr:description><gtr:id>C917EBEB-46A0-4FC7-B937-F61268F53C93</gtr:id><gtr:impact>Award of PancSoc GB&amp;amp;I pump priming grant to validate reported markers of pancreatic cancer in prediagnosis and control samples. Award of CRUK TRICC pilot grant, CRUK BIDD Project grant and Pancreatic cancer UK grant aimed at discovery of serum biomarkers of pancreatic cancer. Identification of promising candidate biomarkers and one publications accepted and another submitted.</gtr:impact><gtr:partnerContribution>Provision of expertise in pancreatic and biliary tract cancers and access to clinical samples for biomarker discoveryAccess to case control samples of benign pancreatic disease and pancreatic cancer for biomarker discovery</gtr:partnerContribution><gtr:piContribution>Proteomic profiling of clinical and control samples of biliary tract cancer and training of a PhD student. Proteomic profiling of pre-diagnosis and matched healthy control serum samples and case controls in a pancreatic cancer biomarker discovery and validation project.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Texas</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>M. D. Anderson Cancer Center</gtr:department><gtr:description>Use of the Multimarker Algorithm for the Early Detection of Ovarian Cancer in Low Risk Women</gtr:description><gtr:id>B296BF72-5AED-4EF3-986F-DF9A9197BAF4</gtr:id><gtr:impact>Experimental work has been completed and data analysis is underway.

The team is multi-disciplinary and are experienced researchers from clinical, biomedical, statistical and proteomic backgrounds</gtr:impact><gtr:partnerContribution>This collaboration with Professor Bast will enable new technologies and new biomarkers to be assessed in UKCTOCS samples.</gtr:partnerContribution><gtr:piContribution>Input into the study design and data interpretation. Preclinical samples from ovarian cancer cases and controls</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>School of Medicine Liverpool</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Medicine and Surgery</gtr:department><gtr:description>Discovery of biomarkers of biliary tract and pancreatic cancer</gtr:description><gtr:id>044A48A0-23D5-424D-B58B-1E20022ACF04</gtr:id><gtr:impact>Award of PancSoc GB&amp;amp;I pump priming grant to validate reported markers of pancreatic cancer in prediagnosis and control samples. Award of CRUK TRICC pilot grant, CRUK BIDD Project grant and Pancreatic cancer UK grant aimed at discovery of serum biomarkers of pancreatic cancer. Identification of promising candidate biomarkers and one publications accepted and another submitted.</gtr:impact><gtr:partnerContribution>Provision of expertise in pancreatic and biliary tract cancers and access to clinical samples for biomarker discoveryAccess to case control samples of benign pancreatic disease and pancreatic cancer for biomarker discovery</gtr:partnerContribution><gtr:piContribution>Proteomic profiling of clinical and control samples of biliary tract cancer and training of a PhD student. Proteomic profiling of pre-diagnosis and matched healthy control serum samples and case controls in a pancreatic cancer biomarker discovery and validation project.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Manchester</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Institute of Cancer Sciences</gtr:department><gtr:description>Proteomic analysis of UKCTOCS serum samples-PROMISE Manchester component</gtr:description><gtr:id>65CAC58B-4FBD-4D62-B967-1874F66F11F7</gtr:id><gtr:impact>Study has started and a number of potential biomarkers for ovarian cancers have been identified in UKCTOCS serum and are under investigation. A translational project grant application to update proteomic methodology has been submitted to the charity 'Target Ovarian Cancer' and the result is pending . The team involved is multi-disciplinary involving researchers from clinical, proteomic and bioinformatics backgrounds</gtr:impact><gtr:partnerContribution>Expertise and access to state of the art facilities</gtr:partnerContribution><gtr:piContribution>Provision of serum and data</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Menon U. Invited Talk: Ovarian cancer screening: where are we now? South Wales Gynaecological Oncology Group - 12th Educational Meeting, Innovations Hub in Cardiiff Bay, 3 Assembly Square, Cardiff Bay, 27 Nov 2015</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>34DEBA78-1423-46B1-ADF5-C913F063DB8C</gtr:id><gtr:impact>Menon U. Invited Talk: Ovarian cancer screening: where are we now? South Wales Gynaecological Oncology Group - 12th Educational Meeting, Innovations Hub in Cardiiff Bay, 3 Assembly Square, Cardiff Bay, 27 Nov 2015</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>UKCTOCS Newsletter</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>4EA64B39-18EC-48B1-8860-C9750A77AB01</gtr:id><gtr:impact>This is difficult to assess as we have more than 200,000 women in our trial and only a very small fraction wrote in to provide feedback.


Women in UKCTOCS were informed of the trial progress and new developments.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2007</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>BBC Radio - Interview with Usha Menon regarding UKCTOCS and ovarian cancer screening</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>2B4F9CD9-6922-4875-9591-6C267295C2F4</gtr:id><gtr:impact>As part of Ovarian Cancer Awareness Month (March), Prof Menon spoke about ovarian cancer, screening for the disease and the preliminary results of the UKCTOCS trial.

Expanding knowledge of ovarian cancer in the general population.</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Menon U. Invited Talk: Memorable research moments in the context of Women's Health, Perinatal Research Meeting UCLH, 4 Mar 2016</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>B79A47F9-82FB-4E85-8E57-78754489A3FD</gtr:id><gtr:impact>Menon U. Invited Talk: Memorable research moments in the context of Women's Health, Perinatal Research Meeting UCLH, 4 Mar 2016</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Media Coverage</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>9DB39B6A-1749-4E19-BCC0-26E90F523DF1</gtr:id><gtr:impact>Numerous magazine articles, newspapers, features and journals.
During 2013 Comments provided for ovarian cancer awareness article following news of death Pierce Brosnan's daughter were published between 17 July 2013 and 2 August 2013 in 23 regional print newspapers and numerous websites:

Raised awareness of ovarian cancer and interest in the group's research. Increase in traffic to ovarian cancer support charities such as Eve Appeal has been noted.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2006,2007,2008,2009,2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Research Feedback Event</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>473AA75B-E7E7-4EA9-94BA-AE7F94CAF9B1</gtr:id><gtr:impact>Approximately 150 people attended the meeting which consisted of oral and poster presentations allowing opportunities for networking between charity supporters, trustees and researchers.

members of the public who attended signed up to receive regular newsletters from the charity and also to participate in fund raising events or make donations to the charity</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Supporters</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Menon U. Invited Talk: Ovarian Cancer - UKCTOCS study: the outcomes, 3rd ENGAGe Patient Seminar, Nice, France, 24 Oct 2015</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>F918F5B7-D9ED-4A3F-89E3-EFAD8D295174</gtr:id><gtr:impact>Menon U. Invited Talk: Ovarian Cancer - UKCTOCS study: the outcomes, 3rd ENGAGe Patient Seminar, Nice, France, 24 Oct 2015</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Hello magazine</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>A90D1771-9FF6-4818-A4D9-499A955E1173</gtr:id><gtr:impact>Interview with Professor Menon

raised awareness for gynaecological cancer and increased traffic too charities such as Eve Appeal</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Laboratory  visits</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>D44FC028-5412-479A-B0B2-94D1BC09D1FF</gtr:id><gtr:impact>The visitors are interested to learn about the work that the research groups do in the field of ovarian cancer. They have an opportunity to speak directly to the researchers and ask questions and to observe samples being processed.

Some of visitors have then made donations to charitable organisations such as Eve Appeal.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2008,2009,2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Menon U. Invited Talk: Ovarian cancer screening - role of biomarkers, 4th Biomarkers in Diagnostics, 8 Oct 2015, Berlin,  Germany</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>AEE198B7-DC47-49F1-8383-8D8B764F7F0D</gtr:id><gtr:impact>Menon U. Invited Talk: Ovarian cancer screening - role of biomarkers, 4th Biomarkers in Diagnostics, 8 Oct 2015, Berlin, Germany</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Jacobs IJ, Menon U, Campbell S, Fallowfield L, Parmar S, and Skates SJ. Live Streamed Presentation: UKCTOCS Mortality Results Public Meeting. Royal College of Obstetricians and Gynecologists, London, UK, 17 Dec 2015</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>4DFE16A5-039B-48E2-BFEF-0D08C55F6B00</gtr:id><gtr:impact>UKCTOCS Mortality Results Public Meeting</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>https://www.youtube.com/watch?v=gD8PGK3ieyw</gtr:url><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Menon U. Invited Talk: Ovarian screening latest news, London Cancer Gynaecology Annual Education Open Meeting, UCLPartners, London, UK, 18 June 2015</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>8950763C-B795-44D6-9519-1C7B10131648</gtr:id><gtr:impact>Menon U. Invited Talk: Ovarian screening latest news, London Cancer Gynaecology Annual Education Open Meeting, UCLPartners, London, UK, 18 June 2015</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>BBC article</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>976DA226-6814-4A63-82CA-0771CE0A2444</gtr:id><gtr:impact>Media coverage of the publication of the prevalence screening results of the UKCTOCS trial.

Wide publising of the work to other medical researchers.</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Menon U. Invited Talk: The UKCTOCS and UKFOCSS trials - what have we learnt so far? 2nd International Ovarian Tumor Analysis Congress (IOTA 2015), 17 Apr 2015, Leuven, Belgium</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>591FE9C0-79A8-4E9A-8926-2E84A762210A</gtr:id><gtr:impact>Menon U. Invited Talk: The UKCTOCS and UKFOCSS trials - what have we learnt so far? 2nd International Ovarian Tumor Analysis Congress (IOTA 2015), 17 Apr 2015, Leuven, Belgium</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Thank you card</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>0A95E88E-60B2-4407-AFE7-C30ABBA3FD99</gtr:id><gtr:impact>With the help of an artist we designed a card to thank women in UKCTOCS which was posted out to approximately 200,000 participants after the close of screening in the trial. Approximately 30,000 women responded within 3 weeks with positive feedback about the trial's impact on them.

As a consequence of the thank you card the study team obtained health status updates from the participants and change of address notifications which will assist for the mailing out our final study questionnaire. In addition, women had an opportunity to undertake fund raising activity via the charity Eve Appeal.
The project relating to generation of the card was presented as the Institute for Women's health annual meeting as a poster</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Paper Presentation</gtr:presentationType><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Menon U. Invited Talk: Ovarian Cancer screening - update from the UK trials, 2015 NCRI Cancer Conference, 1 - 4 Nov 2015, Liverpool, UK</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>2BEB1C31-1D6E-4455-8C7F-37FDA8769899</gtr:id><gtr:impact>Menon U. Invited Talk: Ovarian Cancer screening - update from the UK trials, 2015 NCRI Cancer Conference, 1 - 4 Nov 2015, Liverpool, UK</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Menon U. Invited Talk: UKCTOCS update, RCOG Annual Professional Development Conference, 24 - 26 Nov 2015, London, UK</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>69F7249F-61B4-49DF-A20E-690B97DAE445</gtr:id><gtr:impact>Menon U. Invited Talk: UKCTOCS update, RCOG Annual Professional Development Conference, 24 - 26 Nov 2015, London, UK</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Menon U. Invited Talk: Advances in Ovarian Cancer Research: Exploiting Vulnerabilities, 17 - 20 Oct 2015, Orlando, Florida, USA</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>81FA6551-0BDE-4FB6-AA02-C8F53DB5EFC8</gtr:id><gtr:impact>Menon U. Invited Talk: Advances in Ovarian Cancer Research: Exploiting Vulnerabilities, 17 - 20 Oct 2015, Orlando, Florida, USA</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>118230</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Training Grant: Industrial Case Award</gtr:description><gtr:end>2016-08-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>MR/J006718/1</gtr:fundingRef><gtr:id>A37B4963-7218-4F96-9256-070C64A49C24</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1620000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>PRC Programme Grant -CRUK component</gtr:description><gtr:end>2016-08-02</gtr:end><gtr:fundingOrg>Cancer Research UK (CRUK)</gtr:fundingOrg><gtr:fundingRef>C1005/A12677</gtr:fundingRef><gtr:id>A4068709-F505-4816-9C3B-50ED1D20B1F7</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1100000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Programme of Translational Research in Gynaecological cancer (UCL &amp;amp; Special Trustees UCLH)</gtr:description><gtr:fundingOrg>University College London (UCL)</gtr:fundingOrg><gtr:id>2560168F-008A-44CA-831F-D0F60071C5F0</gtr:id><gtr:sector>Academic/University</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>2303175</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Clinical Trial Grant (UKCTOCS Extension of Screening)</gtr:description><gtr:end>2015-08-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>346B79CE-61B1-4549-9348-32F8415D595E</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>10000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Pancreatic cancer UK Pump priming grant</gtr:description><gtr:fundingOrg>Pancreatic Society of Great Britain and Ireland (PanSoc)</gtr:fundingOrg><gtr:id>1BCE4C52-0EE0-4C27-A5A6-ACE5AB490A35</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>149391</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Pancreatic Cancer UK Project grant</gtr:description><gtr:end>2013-07-02</gtr:end><gtr:fundingOrg>Pancreatic Cancer UK</gtr:fundingOrg><gtr:id>079CC13F-4F7F-468F-B3E6-DF9FFE6D1AB7</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-08-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>800000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>NIHR Biomedical Research Centre at University College London Hospitals NHS Foundation Trust and University College London</gtr:department><gtr:description>UCLH/UCL Comprehensive Biomedical Research Centre (Epigenetic and Genetic analysis in UKCTOCS)</gtr:description><gtr:end>2014-12-02</gtr:end><gtr:fundingOrg>National Institute for Health Research (NIHR)</gtr:fundingOrg><gtr:id>1A085885-8230-46E3-83D7-1B5A5720F16E</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2009-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>145154</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>CRUK TRICC Project Grant</gtr:description><gtr:end>2010-11-02</gtr:end><gtr:fundingOrg>Cancer Research UK (CRUK)</gtr:fundingOrg><gtr:id>09DD9D6B-7853-4EB3-B85B-732F037661BE</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2009-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>6000000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>National Institute for Health Research (NIHR)</gtr:department><gtr:description>DH Service Support Costs UKCTOCS</gtr:description><gtr:end>2015-06-02</gtr:end><gtr:fundingOrg>University College London Hospitals Charity (UCLH)</gtr:fundingOrg><gtr:id>D68B2F0D-7AE4-4D8F-826F-77E1FD3AD554</gtr:id><gtr:sector>Public</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>35647</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>NIHR Biomedical Research Centre at University College London Hospitals NHS Foundation Trust and University College London</gtr:department><gtr:description>UCL/UCLH CBRC New Initiatives</gtr:description><gtr:end>2010-01-02</gtr:end><gtr:fundingOrg>National Institute for Health Research (NIHR)</gtr:fundingOrg><gtr:id>171E6B50-ADCF-4E5F-B1E3-D66799347744</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>185000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>CRUK BIDD Project Grant</gtr:description><gtr:end>2013-03-02</gtr:end><gtr:fundingOrg>Cancer Research UK (CRUK)</gtr:fundingOrg><gtr:id>BDEFA49A-7966-416A-AE55-382461487850</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>90000</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Seventh Framework Programme (FP7)</gtr:department><gtr:description>EU FP7</gtr:description><gtr:fundingOrg>Community Research and Development Information Service (CORDIS)</gtr:fundingOrg><gtr:fundingRef>HEALTH-F5-2012-305428</gtr:fundingRef><gtr:id>0B81A729-9328-4372-B898-4B91F39EAA4F</gtr:id><gtr:sector>Public</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1641890</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>PRC Programme grant - EVE Appeal component</gtr:description><gtr:end>2016-08-02</gtr:end><gtr:fundingOrg>The Eve Appeal</gtr:fundingOrg><gtr:id>FD9843A0-43A2-4907-994D-EBCD82779E9E</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>100000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>National Institute for Health Research (NIHR)</gtr:department><gtr:description>NIHR UCLH Biomedical Research Centre Cancer Programme Funding</gtr:description><gtr:end>2016-05-02</gtr:end><gtr:fundingOrg>University College London Hospitals Charity (UCLH)</gtr:fundingOrg><gtr:id>E58697A3-2936-4973-9FEB-A402B66C6291</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2014-06-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Ovarian cancer awareness consultation</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>56A02B1A-E123-43E7-8A7C-771FC1CEDD28</gtr:id><gtr:type>Participation in a national consultation</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Training of UKCTOCS sonographers</gtr:description><gtr:geographicReach>Local/Municipal/Regional</gtr:geographicReach><gtr:id>71FBE7F4-777A-409C-AA8A-30DBE39F4EDE</gtr:id><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Database system that assists in running of the trial.</gtr:description><gtr:id>902FECAE-FFE5-499E-B0F5-32005C5E862E</gtr:id><gtr:impact>Streamlined running of all aspects of UKCTOCS.</gtr:impact><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>UKCTOCS trial management system</gtr:title><gtr:type>Biological samples</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>The identities of low-molecular weight serum peptides found using our profiling platform has been determined and a database of these assembled for reference in future profiling studies</gtr:description><gtr:id>ED3940D9-782E-4312-9CCB-2F7C47C38BE3</gtr:id><gtr:impact>Publication of the data and use in other biomarker discovery projects</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>A database of serum peptide identifications</gtr:title><gtr:type>Biological samples</gtr:type><gtr:yearFirstProvided>2009</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>We are databasing static ultrasound images collected during the UKCTOCS trial which will serve as an electronic source for review and management of women on the trial. In addition it enables training and refinement of techniques for assessing the ultrasound images. There is huge potential also for pursuing future research in imaging postmenopausal ovaries in health and in cancer.
Currently have 255,472 archived TVS examinations.</gtr:description><gtr:id>17EDF36C-D425-4AC6-AE5B-D2E7FFDC5416</gtr:id><gtr:impact>The database is currently incomplete but represents a major resource for investigation and training. The major benefit of this electronic resource is ease of access and rapidity to volunteer scanning results. It also provides a means for checking the quality of ultrasonography in UKCTOCS. In terms of research efforts it represent a significant resource for a variety of analyses, including assessment of ultrasound findings in malignant lesions in ovarian and other gynaecological cancers. The URA also has the potential to help refine and set standards for ultrasound image analysis.</gtr:impact><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Ultrasound Record Archive</gtr:title><gtr:type>Biological samples</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>A platform incorporating robotic extraction of peptides from serum on magnetic beads and sample spotting linked to automated MALDI-TOF MS data acquisition was developed for high-throughput profiling of low-mass polypeptides in the serum of clinical sample sets</gtr:description><gtr:id>B9F7055A-E61D-4268-9312-EAA00463C386</gtr:id><gtr:impact>The platform has been applied on mutliple biomarker discovery projects using serum from case control collections and pre-diagnosis samples from UKCTOCS</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>A reproducible platform for serum peptide profiling</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2009</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs><gtr:spinOutOutput><gtr:companyName>Abcodia</gtr:companyName><gtr:description>Abcodia is involved in discovery and validation of molecular biomarkers for disease diagnosis and screening. It is the means by which diagnostic, pharmaceutical and technology companies can access serum samples collected in UKCTOCS for the purpose of ethical biomarker validation and discovery. Abcodia are part of the global alliance 'Early Diagnosis Consortium' with Cancer Research UK and Cancer Research Technology 
Please see website for further information: http://abcodia.com/</gtr:description><gtr:id>085FE534-8AAC-4875-B30B-C5F01870B7A9</gtr:id><gtr:impact>The company is now involved in a number of collaborations including a nested case control study in pancreatic cancer. In Dec 2012,Abcodia won 4 prizes at the NatWest Start up awards : (1) the NatWest Start-Up business of the year (Top prize); (2) Most Innovative business of the year; (3) Best Angel or VC backed business of the year; and (4) Start-Up business woman of the year (Julie Barnes as our Abcodia CEO). 
 Abcodia have steadily been building up th number of collaborations with a variety of partners. To date the company are involved in 13 projects.</gtr:impact><gtr:url>http://www.abcodia.com/</gtr:url><gtr:yearCompanyFormed>2010</gtr:yearCompanyFormed></gtr:spinOutOutput></gtr:spinOutOutputs></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/7792F839-7844-4397-8C2D-9396F8F7F780"><gtr:id>7792F839-7844-4397-8C2D-9396F8F7F780</gtr:id><gtr:title>Postmenopausal women undergoing transvaginal ultrasound screening prefer not to have chaperones.</gtr:title><gtr:parentPublicationTitle>BJOG : an international journal of obstetrics and gynaecology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/051dea896965c11682564b739821a77d"><gtr:id>051dea896965c11682564b739821a77d</gtr:id><gtr:otherNames>Sharma A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>1470-0328</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/FB03F83B-F184-4916-954D-2BF412A36679"><gtr:id>FB03F83B-F184-4916-954D-2BF412A36679</gtr:id><gtr:title>Progress and challenges in screening for early detection of ovarian cancer.</gtr:title><gtr:parentPublicationTitle>Molecular &amp; cellular proteomics : MCP</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/5040a670019c719b62bda30e0b2ab3cf"><gtr:id>5040a670019c719b62bda30e0b2ab3cf</gtr:id><gtr:otherNames>Jacobs IJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2004-01-01</gtr:date><gtr:issn>1535-9476</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/77971BD6-44A7-416F-A87D-2E7ACBEFABF8"><gtr:id>77971BD6-44A7-416F-A87D-2E7ACBEFABF8</gtr:id><gtr:title>Association of serum sex steroid receptor bioactivity and sex steroid hormones with breast cancer risk in postmenopausal women.</gtr:title><gtr:parentPublicationTitle>Endocrine-related cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/c1802a3bd19410654f162e2fff2221b8"><gtr:id>c1802a3bd19410654f162e2fff2221b8</gtr:id><gtr:otherNames>Fourkala EO</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1351-0088</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/E80D1101-1182-4E0F-81BC-A4E7D7FD4140"><gtr:id>E80D1101-1182-4E0F-81BC-A4E7D7FD4140</gtr:id><gtr:title>Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS).</gtr:title><gtr:parentPublicationTitle>The Lancet. Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/5437a6f69334797e7de5165b0ad10976"><gtr:id>5437a6f69334797e7de5165b0ad10976</gtr:id><gtr:otherNames>Menon U</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1470-2045</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/5793A2EB-5D0D-4B74-9A5F-C0EF00F39600"><gtr:id>5793A2EB-5D0D-4B74-9A5F-C0EF00F39600</gtr:id><gtr:title>Awareness of ovarian cancer risk factors, beliefs and attitudes towards screening: baseline survey of 21,715 women participating in the UK Collaborative Trial of Ovarian Cancer Screening.</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/4427bd0ed7bc34790b20866189c16d15"><gtr:id>4427bd0ed7bc34790b20866189c16d15</gtr:id><gtr:otherNames>Fallowfield L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/1CCE197D-FECD-4016-8BC3-3E1242D79E94"><gtr:id>1CCE197D-FECD-4016-8BC3-3E1242D79E94</gtr:id><gtr:title>Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial.</gtr:title><gtr:parentPublicationTitle>Lancet (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/5040a670019c719b62bda30e0b2ab3cf"><gtr:id>5040a670019c719b62bda30e0b2ab3cf</gtr:id><gtr:otherNames>Jacobs IJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0140-6736</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/5D3E027D-67DE-49C3-A795-935706D02B23"><gtr:id>5D3E027D-67DE-49C3-A795-935706D02B23</gtr:id><gtr:title>International Conference on Ovarian Cancer Screening: 29th-30th November 2011, Royal College of Physicians, London. Foreword.</gtr:title><gtr:parentPublicationTitle>International journal of gynecological cancer : official journal of the International Gynecological Cancer Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/5437a6f69334797e7de5165b0ad10976"><gtr:id>5437a6f69334797e7de5165b0ad10976</gtr:id><gtr:otherNames>Menon U</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1048-891X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/09A94AEE-6F83-4AE8-BDD9-921E9CC6B37B"><gtr:id>09A94AEE-6F83-4AE8-BDD9-921E9CC6B37B</gtr:id><gtr:title>Cancer-associated autoantibodies to MUC1 and MUC4--a blinded case-control study of colorectal cancer in UK collaborative trial of ovarian cancer screening.</gtr:title><gtr:parentPublicationTitle>International journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/0749e62a12aa11fb1f13347b35743eb2"><gtr:id>0749e62a12aa11fb1f13347b35743eb2</gtr:id><gtr:otherNames>Pedersen JW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0020-7136</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/53BF43F6-47B8-456C-9EE7-41315D408FD0"><gtr:id>53BF43F6-47B8-456C-9EE7-41315D408FD0</gtr:id><gtr:title>Identifying hopelessness in population research: a validation study of two brief measures of hopelessness.</gtr:title><gtr:parentPublicationTitle>BMJ open</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/dfd1fccf39a36b074b47be7f9428444f"><gtr:id>dfd1fccf39a36b074b47be7f9428444f</gtr:id><gtr:otherNames>Fraser L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2044-6055</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/E2F42C09-2CBA-496E-AAB8-6A8D201C5F7C"><gtr:id>E2F42C09-2CBA-496E-AAB8-6A8D201C5F7C</gtr:id><gtr:title>Association of skirt size and postmenopausal breast cancer risk in older women: a cohort study within the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS).</gtr:title><gtr:parentPublicationTitle>BMJ open</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/c1802a3bd19410654f162e2fff2221b8"><gtr:id>c1802a3bd19410654f162e2fff2221b8</gtr:id><gtr:otherNames>Fourkala EO</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2044-6055</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/576AD9A7-ED6E-447D-A550-5A3F878E5395"><gtr:id>576AD9A7-ED6E-447D-A550-5A3F878E5395</gtr:id><gtr:title>Assessing the malignant potential of ovarian inclusion cysts in postmenopausal women within the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a prospective cohort study.</gtr:title><gtr:parentPublicationTitle>BJOG : an international journal of obstetrics and gynaecology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/051dea896965c11682564b739821a77d"><gtr:id>051dea896965c11682564b739821a77d</gtr:id><gtr:otherNames>Sharma A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1470-0328</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/5ECC2190-748D-4074-BE6A-B4B1F4362549"><gtr:id>5ECC2190-748D-4074-BE6A-B4B1F4362549</gtr:id><gtr:title>Development of a multimarker assay for early detection of ovarian cancer.</gtr:title><gtr:parentPublicationTitle>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/f458c337dbced971da25bfbcbc8cd4d1"><gtr:id>f458c337dbced971da25bfbcbc8cd4d1</gtr:id><gtr:otherNames>Yurkovetsky Z</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0732-183X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/8DC0B120-39A4-4D48-8E37-1CE0636D1962"><gtr:id>8DC0B120-39A4-4D48-8E37-1CE0636D1962</gtr:id><gtr:title>Ovarian cancer screening: UKCTOCS trial - Authors' reply.</gtr:title><gtr:parentPublicationTitle>Lancet (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/5040a670019c719b62bda30e0b2ab3cf"><gtr:id>5040a670019c719b62bda30e0b2ab3cf</gtr:id><gtr:otherNames>Jacobs IJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0140-6736</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/528F86B5-7539-4E48-A9C0-7E61212957AA"><gtr:id>528F86B5-7539-4E48-A9C0-7E61212957AA</gtr:id><gtr:title>Mucins and Cancer</gtr:title><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/4270df9066e8abfa046f8296dbea116d"><gtr:id>4270df9066e8abfa046f8296dbea116d</gtr:id><gtr:otherNames>Fourkala E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/188E332C-DD52-4A64-A0A6-35285BA333E6"><gtr:id>188E332C-DD52-4A64-A0A6-35285BA333E6</gtr:id><gtr:title>Psychological morbidity associated with ovarian cancer screening: results from more than 23,000 women in the randomised trial of ovarian cancer screening (UKCTOCS).</gtr:title><gtr:parentPublicationTitle>BJOG : an international journal of obstetrics and gynaecology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/746d6e4c7a1e8580f69066c5c55eb1b5"><gtr:id>746d6e4c7a1e8580f69066c5c55eb1b5</gtr:id><gtr:otherNames>Barrett J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1470-0328</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/806207DA-DDBA-4BA0-8D72-69B7AD7999A4"><gtr:id>806207DA-DDBA-4BA0-8D72-69B7AD7999A4</gtr:id><gtr:title>The sine qua non of discovering novel biomarkers for early detection of ovarian cancer: carefully selected preclinical samples.</gtr:title><gtr:parentPublicationTitle>Cancer prevention research (Philadelphia, Pa.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/f05c6525a00e9dfbcaa3a5211fbcf467"><gtr:id>f05c6525a00e9dfbcaa3a5211fbcf467</gtr:id><gtr:otherNames>Jacobs I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1940-6215</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/281D13F1-7066-425E-993F-EEB67847DDE9"><gtr:id>281D13F1-7066-425E-993F-EEB67847DDE9</gtr:id><gtr:title>Highly accurate detection of ovarian cancer using CA125 but limited improvement with serum matrix-assisted laser desorption/ionization time-of-flight mass spectrometry profiling.</gtr:title><gtr:parentPublicationTitle>International journal of gynecological cancer : official journal of the International Gynecological Cancer Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/2cd7cc15bf278cda9234660cde466127"><gtr:id>2cd7cc15bf278cda9234660cde466127</gtr:id><gtr:otherNames>Tiss A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1048-891X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/BB658144-2F0F-4BDC-BB0E-309ABEF957F5"><gtr:id>BB658144-2F0F-4BDC-BB0E-309ABEF957F5</gtr:id><gtr:title>Ovarian cancer tumor markers and screening In Berek and Hacker's Gynaecological Oncology</gtr:title><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/4b05c8f22e6815a1f325e5514637fea3"><gtr:id>4b05c8f22e6815a1f325e5514637fea3</gtr:id><gtr:otherNames>Gentry-Maharaj A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:isbn>-</gtr:isbn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/565C1D59-0583-42AC-AA3B-5B4BEDEAF3BF"><gtr:id>565C1D59-0583-42AC-AA3B-5B4BEDEAF3BF</gtr:id><gtr:title>Validity of self-reported hysterectomy: a prospective cohort study within the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS).</gtr:title><gtr:parentPublicationTitle>BMJ open</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/4b05c8f22e6815a1f325e5514637fea3"><gtr:id>4b05c8f22e6815a1f325e5514637fea3</gtr:id><gtr:otherNames>Gentry-Maharaj A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2044-6055</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/91C193D2-FAEC-4E73-A420-80C2F4A1B862"><gtr:id>91C193D2-FAEC-4E73-A420-80C2F4A1B862</gtr:id><gtr:title>Early detection of cancer in the general population: a blinded case-control study of p53 autoantibodies in colorectal cancer.</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/0749e62a12aa11fb1f13347b35743eb2"><gtr:id>0749e62a12aa11fb1f13347b35743eb2</gtr:id><gtr:otherNames>Pedersen JW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/D5DB6935-2599-400E-BA6E-FC3C4AF7D18F"><gtr:id>D5DB6935-2599-400E-BA6E-FC3C4AF7D18F</gtr:id><gtr:title>Conformal predictors in early diagnostics of ovarian and breast cancers</gtr:title><gtr:parentPublicationTitle>Progress in Artificial Intelligence</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/84ebf8ae840f2fb8813384582b293eae"><gtr:id>84ebf8ae840f2fb8813384582b293eae</gtr:id><gtr:otherNames>Devetyarov D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/D6B44E1C-F190-4A42-A130-909B75FC9ECE"><gtr:id>D6B44E1C-F190-4A42-A130-909B75FC9ECE</gtr:id><gtr:title>Psychosocial Factors Associated With Withdrawal From the United Kingdom Collaborative Trial of Ovarian Cancer Screening After 1 Episode of Repeat Screening.</gtr:title><gtr:parentPublicationTitle>International journal of gynecological cancer : official journal of the International Gynecological Cancer Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/c3d9fcac32bedd45dca8329d4ad63648"><gtr:id>c3d9fcac32bedd45dca8329d4ad63648</gtr:id><gtr:otherNames>Jenkins V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1048-891X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/1D01CEFE-92F5-4CA2-8AFE-554E82B9B6B0"><gtr:id>1D01CEFE-92F5-4CA2-8AFE-554E82B9B6B0</gtr:id><gtr:title>Risk Algorithm Using Serial Biomarker Measurements Doubles the Number of Screen-Detected Cancers Compared With a Single-Threshold Rule in the United Kingdom Collaborative Trial of Ovarian Cancer Screening.</gtr:title><gtr:parentPublicationTitle>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/5437a6f69334797e7de5165b0ad10976"><gtr:id>5437a6f69334797e7de5165b0ad10976</gtr:id><gtr:otherNames>Menon U</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0732-183X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/7FBE3C1E-3D81-42BD-A5E2-69C917438F40"><gtr:id>7FBE3C1E-3D81-42BD-A5E2-69C917438F40</gtr:id><gtr:title>Quality assurance and its impact on ovarian visualization rates in the multicenter United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS).</gtr:title><gtr:parentPublicationTitle>Ultrasound in obstetrics &amp; gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/051dea896965c11682564b739821a77d"><gtr:id>051dea896965c11682564b739821a77d</gtr:id><gtr:otherNames>Sharma A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0960-7692</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/70165F28-4279-4590-9D69-3EE8A5272F23"><gtr:id>70165F28-4279-4590-9D69-3EE8A5272F23</gtr:id><gtr:title>Peptides generated ex vivo from serum proteins by tumor-specific exopeptidases are not useful biomarkers in ovarian cancer.</gtr:title><gtr:parentPublicationTitle>Clinical chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/d56661fabeab58b91bce97c183c6571d"><gtr:id>d56661fabeab58b91bce97c183c6571d</gtr:id><gtr:otherNames>Timms JF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0009-9147</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/9C46A3DA-0C29-411A-B061-D7AB30E77202"><gtr:id>9C46A3DA-0C29-411A-B061-D7AB30E77202</gtr:id><gtr:title>OSPACS: Ultrasound image management system.</gtr:title><gtr:parentPublicationTitle>Source code for biology and medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/bf00164c88ab53510ce69ca75566aa4a"><gtr:id>bf00164c88ab53510ce69ca75566aa4a</gtr:id><gtr:otherNames>Stott W</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1751-0473</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/735A1851-D06A-42E9-99C3-21EEFC24687C"><gtr:id>735A1851-D06A-42E9-99C3-21EEFC24687C</gtr:id><gtr:title>Factors affecting visualization of postmenopausal ovaries: descriptive study from the multicenter United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS).</gtr:title><gtr:parentPublicationTitle>Ultrasound in obstetrics &amp; gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/051dea896965c11682564b739821a77d"><gtr:id>051dea896965c11682564b739821a77d</gtr:id><gtr:otherNames>Sharma A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0960-7692</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/0A6126B2-9DA5-4685-9314-6ACFE5ECDFEB"><gtr:id>0A6126B2-9DA5-4685-9314-6ACFE5ECDFEB</gtr:id><gtr:title>Psychosocial Factors Associated With Withdrawal From the United Kingdom Collaborative Trial of Ovarian Cancer Screening After 1 Episode of Repeat Screening.</gtr:title><gtr:parentPublicationTitle>International journal of gynecological cancer : official journal of the International Gynecological Cancer Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/c3d9fcac32bedd45dca8329d4ad63648"><gtr:id>c3d9fcac32bedd45dca8329d4ad63648</gtr:id><gtr:otherNames>Jenkins V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1048-891X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/02812C61-5689-4977-AEA6-424071FBDFC4"><gtr:id>02812C61-5689-4977-AEA6-424071FBDFC4</gtr:id><gtr:title>Pelvic Cancer Surgery</gtr:title><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/4b05c8f22e6815a1f325e5514637fea3"><gtr:id>4b05c8f22e6815a1f325e5514637fea3</gtr:id><gtr:otherNames>Gentry-Maharaj A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:isbn>-</gtr:isbn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/D309C1EE-47EE-49A4-B5C7-890D9C3ED354"><gtr:id>D309C1EE-47EE-49A4-B5C7-890D9C3ED354</gtr:id><gtr:title>Principles and Practice of Gynecologic Oncology</gtr:title><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/aeaf8284f75e50f597df5516351e51c3"><gtr:id>aeaf8284f75e50f597df5516351e51c3</gtr:id><gtr:otherNames>Gentry-Maharaj, Aleksandra</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/30BD8B5D-6B5E-47C4-AF52-8942FE2B22F0"><gtr:id>30BD8B5D-6B5E-47C4-AF52-8942FE2B22F0</gtr:id><gtr:title>Sensitivity of transvaginal ultrasound screening for endometrial cancer in postmenopausal women: a case-control study within the UKCTOCS cohort.</gtr:title><gtr:parentPublicationTitle>The Lancet. Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/f05c6525a00e9dfbcaa3a5211fbcf467"><gtr:id>f05c6525a00e9dfbcaa3a5211fbcf467</gtr:id><gtr:otherNames>Jacobs I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1470-2045</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/F7FF51B9-BEE4-45F4-8AD8-AAEC7A09FEDA"><gtr:id>F7FF51B9-BEE4-45F4-8AD8-AAEC7A09FEDA</gtr:id><gtr:title>Autoantibodies to MUC1 glycopeptides cannot be used as a screening assay for early detection of breast, ovarian, lung or pancreatic cancer.</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/a9b0e2d4ecf5945bcd73c364f8112c9c"><gtr:id>a9b0e2d4ecf5945bcd73c364f8112c9c</gtr:id><gtr:otherNames>Burford B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/98DC9051-FAD9-4399-B2CE-61456D1AC24A"><gtr:id>98DC9051-FAD9-4399-B2CE-61456D1AC24A</gtr:id><gtr:title>Acceptance of transvaginal sonography by postmenopausal women participating in the United Kingdom Collaborative Trial of Ovarian Cancer Screening.</gtr:title><gtr:parentPublicationTitle>Ultrasound in obstetrics &amp; gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/4b05c8f22e6815a1f325e5514637fea3"><gtr:id>4b05c8f22e6815a1f325e5514637fea3</gtr:id><gtr:otherNames>Gentry-Maharaj A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0960-7692</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/16F64F27-CA3C-4E7D-9972-AFF5062121AE"><gtr:id>16F64F27-CA3C-4E7D-9972-AFF5062121AE</gtr:id><gtr:title>Risk Algorithm Using Serial Biomarker Measurements Doubles the Number of Screen-Detected Cancers Compared With a Single-Threshold Rule in the United Kingdom Collaborative Trial of Ovarian Cancer Screening.</gtr:title><gtr:parentPublicationTitle>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/5437a6f69334797e7de5165b0ad10976"><gtr:id>5437a6f69334797e7de5165b0ad10976</gtr:id><gtr:otherNames>Menon U</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0732-183X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/497EE35A-32E4-4C43-9988-7AC77DC0EDD7"><gtr:id>497EE35A-32E4-4C43-9988-7AC77DC0EDD7</gtr:id><gtr:title>Psychological morbidity associated with ovarian cancer screening: results from more than 23,000 women in the randomised trial of ovarian cancer screening (UKCTOCS).</gtr:title><gtr:parentPublicationTitle>BJOG : an international journal of obstetrics and gynaecology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/746d6e4c7a1e8580f69066c5c55eb1b5"><gtr:id>746d6e4c7a1e8580f69066c5c55eb1b5</gtr:id><gtr:otherNames>Barrett J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1470-0328</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/78105AE2-4B8E-4F34-8B6A-A24673652592"><gtr:id>78105AE2-4B8E-4F34-8B6A-A24673652592</gtr:id><gtr:title>Use and perceived efficacy of complementary and alternative medicines after discontinuation of hormone therapy: a nested United Kingdom Collaborative Trial of Ovarian Cancer Screening cohort study.</gtr:title><gtr:parentPublicationTitle>Menopause (New York, N.Y.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/4b05c8f22e6815a1f325e5514637fea3"><gtr:id>4b05c8f22e6815a1f325e5514637fea3</gtr:id><gtr:otherNames>Gentry-Maharaj A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1072-3714</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/144B31AC-167A-4866-95BC-F92219B5B797"><gtr:id>144B31AC-167A-4866-95BC-F92219B5B797</gtr:id><gtr:title>Sensitivity of transvaginal ultrasound screening for endometrial cancer in postmenopausal women: a case-control study within the UKCTOCS cohort.</gtr:title><gtr:parentPublicationTitle>The Lancet. Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/f05c6525a00e9dfbcaa3a5211fbcf467"><gtr:id>f05c6525a00e9dfbcaa3a5211fbcf467</gtr:id><gtr:otherNames>Jacobs I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1470-2045</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/E1AFF6D2-68C8-4816-9181-2E3ECBF5BE44"><gtr:id>E1AFF6D2-68C8-4816-9181-2E3ECBF5BE44</gtr:id><gtr:title>Risk of epithelial ovarian cancer in asymptomatic women with ultrasound-detected ovarian masses: a prospective cohort study within the UK collaborative trial of ovarian cancer screening (UKCTOCS).</gtr:title><gtr:parentPublicationTitle>Ultrasound in obstetrics &amp; gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/051dea896965c11682564b739821a77d"><gtr:id>051dea896965c11682564b739821a77d</gtr:id><gtr:otherNames>Sharma A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0960-7692</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/0521C393-2CC2-482D-82BA-9F4BFD57A769"><gtr:id>0521C393-2CC2-482D-82BA-9F4BFD57A769</gtr:id><gtr:title>Ovarian cancer screening--current status, future directions.</gtr:title><gtr:parentPublicationTitle>Gynecologic oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/5437a6f69334797e7de5165b0ad10976"><gtr:id>5437a6f69334797e7de5165b0ad10976</gtr:id><gtr:otherNames>Menon U</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0090-8258</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/8BDFDB05-3EAB-4EE1-AAAD-8C0DA03091BA"><gtr:id>8BDFDB05-3EAB-4EE1-AAAD-8C0DA03091BA</gtr:id><gtr:title>A BRCA1-mutation associated DNA methylation signature in blood cells predicts sporadic breast cancer incidence and survival.</gtr:title><gtr:parentPublicationTitle>Genome medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/f25435dd372c9714ddd54dfca15b19f5"><gtr:id>f25435dd372c9714ddd54dfca15b19f5</gtr:id><gtr:otherNames>Anjum S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1756-994X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/694B9199-A791-4F78-BDC6-CB620A6CB204"><gtr:id>694B9199-A791-4F78-BDC6-CB620A6CB204</gtr:id><gtr:title>Reply to P.F. Pinsky, C.P. Crum, and M.W. McIntosh et al.</gtr:title><gtr:parentPublicationTitle>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/5437a6f69334797e7de5165b0ad10976"><gtr:id>5437a6f69334797e7de5165b0ad10976</gtr:id><gtr:otherNames>Menon U</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0732-183X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/9B76EB2F-0B6F-4492-9A3A-79173EB99959"><gtr:id>9B76EB2F-0B6F-4492-9A3A-79173EB99959</gtr:id><gtr:title>Ovarian cancer screening and mortality.</gtr:title><gtr:parentPublicationTitle>JAMA</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/5437a6f69334797e7de5165b0ad10976"><gtr:id>5437a6f69334797e7de5165b0ad10976</gtr:id><gtr:otherNames>Menon U</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0098-7484</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/74BEDA59-47D3-4DD8-BE23-9E1ED0B2CEAE"><gtr:id>74BEDA59-47D3-4DD8-BE23-9E1ED0B2CEAE</gtr:id><gtr:title>Early detection of ovarian cancer in samples pre-diagnosis using CA125 and MALDI-MS peaks.</gtr:title><gtr:parentPublicationTitle>Cancer genomics &amp; proteomics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/d56661fabeab58b91bce97c183c6571d"><gtr:id>d56661fabeab58b91bce97c183c6571d</gtr:id><gtr:otherNames>Timms JF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1109-6535</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/FD58ED44-6E82-4805-A780-77722096183F"><gtr:id>FD58ED44-6E82-4805-A780-77722096183F</gtr:id><gtr:title>Genetics for Health Professionals in Cancer Care</gtr:title><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/4b05c8f22e6815a1f325e5514637fea3"><gtr:id>4b05c8f22e6815a1f325e5514637fea3</gtr:id><gtr:otherNames>Gentry-Maharaj A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:isbn>-</gtr:isbn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/98AEB636-2920-44BB-A860-968A44D2E725"><gtr:id>98AEB636-2920-44BB-A860-968A44D2E725</gtr:id><gtr:title>The UKCTOCS experience--reasons for hope?</gtr:title><gtr:parentPublicationTitle>International journal of gynecological cancer : official journal of the International Gynecological Cancer Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/5437a6f69334797e7de5165b0ad10976"><gtr:id>5437a6f69334797e7de5165b0ad10976</gtr:id><gtr:otherNames>Menon U</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1048-891X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/92951B27-F821-44F2-A193-0CA64A7B4F08"><gtr:id>92951B27-F821-44F2-A193-0CA64A7B4F08</gtr:id><gtr:title>Prevalence, frequency and problem rating of hot flushes persist in older postmenopausal women: impact of age, body mass index, hysterectomy, hormone therapy use, lifestyle and mood in a cross-sectional cohort study of 10,418 British women aged 54-65.</gtr:title><gtr:parentPublicationTitle>BJOG : an international journal of obstetrics and gynaecology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/6e3b4487879dfa186445e7735349b5c6"><gtr:id>6e3b4487879dfa186445e7735349b5c6</gtr:id><gtr:otherNames>Hunter MS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1470-0328</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/94FB4071-24AB-4E9A-B793-9A3F154804B5"><gtr:id>94FB4071-24AB-4E9A-B793-9A3F154804B5</gtr:id><gtr:title>Predictive value of symptoms for ovarian cancer: comparison of symptoms reported by questionnaire, interview, and general practitioner notes.</gtr:title><gtr:parentPublicationTitle>Journal of the National Cancer Institute</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/f61651130ee7c62d38b8dee3a8f60db2"><gtr:id>f61651130ee7c62d38b8dee3a8f60db2</gtr:id><gtr:otherNames>Lim AW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0027-8874</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/463A8D45-B6F9-4309-92CE-507314600121"><gtr:id>463A8D45-B6F9-4309-92CE-507314600121</gtr:id><gtr:title>Serum CA19-9 is significantly upregulated up to 2 years before diagnosis with pancreatic cancer: implications for early disease detection.</gtr:title><gtr:parentPublicationTitle>Clinical cancer research : an official journal of the American Association for Cancer Research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/54f41728e220a66a15fac108f33cb875"><gtr:id>54f41728e220a66a15fac108f33cb875</gtr:id><gtr:otherNames>O'Brien DP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1078-0432</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/B8F9A659-FFE3-4A3E-B98B-C638E134DC53"><gtr:id>B8F9A659-FFE3-4A3E-B98B-C638E134DC53</gtr:id><gtr:title>Recruitment to multicentre trials--lessons from UKCTOCS: descriptive study.</gtr:title><gtr:parentPublicationTitle>BMJ (Clinical research ed.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/5437a6f69334797e7de5165b0ad10976"><gtr:id>5437a6f69334797e7de5165b0ad10976</gtr:id><gtr:otherNames>Menon U</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0959-535X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/A1DD389E-23F0-43A8-B037-F7FEF1BB6606"><gtr:id>A1DD389E-23F0-43A8-B037-F7FEF1BB6606</gtr:id><gtr:title>Ovarian cancer.</gtr:title><gtr:parentPublicationTitle>Nature reviews. Disease primers</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/39f68e08c4aaa24ec3a817da328ce58d"><gtr:id>39f68e08c4aaa24ec3a817da328ce58d</gtr:id><gtr:otherNames>Matulonis UA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2056-676X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/BED9D968-BF76-485D-BE5D-6DA7B32C40C8"><gtr:id>BED9D968-BF76-485D-BE5D-6DA7B32C40C8</gtr:id><gtr:title>Decline in use of hormone therapy among postmenopausal women in the United Kingdom.</gtr:title><gtr:parentPublicationTitle>Menopause (New York, N.Y.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/5437a6f69334797e7de5165b0ad10976"><gtr:id>5437a6f69334797e7de5165b0ad10976</gtr:id><gtr:otherNames>Menon U</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>1072-3714</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/FAD44757-CC6F-4F28-904E-945031FF2D74"><gtr:id>FAD44757-CC6F-4F28-904E-945031FF2D74</gtr:id><gtr:title>Histological confirmation of breast cancer registration and self-reporting in England and Wales: a cohort study within the UK Collaborative Trial of Ovarian Cancer Screening.</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/c1802a3bd19410654f162e2fff2221b8"><gtr:id>c1802a3bd19410654f162e2fff2221b8</gtr:id><gtr:otherNames>Fourkala EO</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/B8AB7A6D-1A86-4828-8170-3DC994CDABC0"><gtr:id>B8AB7A6D-1A86-4828-8170-3DC994CDABC0</gtr:id><gtr:title>Concordance of National Cancer Registration with self-reported breast, bowel and lung cancer in England and Wales: a prospective cohort study within the UK Collaborative Trial of Ovarian Cancer Screening.</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/4b05c8f22e6815a1f325e5514637fea3"><gtr:id>4b05c8f22e6815a1f325e5514637fea3</gtr:id><gtr:otherNames>Gentry-Maharaj A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/D6034A4D-6317-4F66-9D0A-8C06A4F6BBFF"><gtr:id>D6034A4D-6317-4F66-9D0A-8C06A4F6BBFF</gtr:id><gtr:title>Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial</gtr:title><gtr:parentPublicationTitle>The Lancet</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/f05c6525a00e9dfbcaa3a5211fbcf467"><gtr:id>f05c6525a00e9dfbcaa3a5211fbcf467</gtr:id><gtr:otherNames>Jacobs I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/57F6C9FB-BC8A-4EA8-BF8E-3CC53A28094C"><gtr:id>57F6C9FB-BC8A-4EA8-BF8E-3CC53A28094C</gtr:id><gtr:title>Ovarian cancer screening has no effect on disease-specific mortality.</gtr:title><gtr:parentPublicationTitle>Evidence-based medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/5437a6f69334797e7de5165b0ad10976"><gtr:id>5437a6f69334797e7de5165b0ad10976</gtr:id><gtr:otherNames>Menon U</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1356-5524</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/8406F324-F07C-4DF7-82A6-E58C9CD139A6"><gtr:id>8406F324-F07C-4DF7-82A6-E58C9CD139A6</gtr:id><gtr:title>Impact on mortality and cancer incidence rates of using random invitation from population registers for recruitment to trials.</gtr:title><gtr:parentPublicationTitle>Trials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/cf39766f2c58c53463ac157701e94718"><gtr:id>cf39766f2c58c53463ac157701e94718</gtr:id><gtr:otherNames>Burnell M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1745-6215</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G9901012</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>5C2ACE0A-A29E-4DCC-9F5A-B00BFAB172B9</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>4.4  Population screening</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>